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Summary.-After the intravenous injection of Walker 256 tumour cells into rats the
platelet count decreased rapidly and remained low during the following period of
observation. The platelet decrease wascloselyrelated to thenumberofcellsinjected.
Intra-arterial tumour cellinjections required aconsiderablyhigher tumourcellcount
to produce a comparable thrombocytopenia. Non-viable tumour cells and tumour
cell fragments induced a similar decrease of circulating platelets. Neither viable
tumour cells nor tumour cell fragments aggregated rat platelets in vitro. The
presence offibrin monomers in tumour cell injected animals suggested intravascular
fibrin deposition; the plasma fibrinogen level, however, did not decrease signifi-
cantly. Isotope studies using 51Cr labelled platelets revealed a rapid disappearance
of the platelets from the circulation and their trapping in' the lung-the primary
site of tumour cell lodgement. Dipyridamole and ancrod pretreatment did not
influence the decrease of platelets and their accumulation in the lung after tumour
cell injection. In contrast, heparin completely prevented the thrombocytopenia and
the platelet trapping in the lung. From the present experiments it is concluded that
embolic tumour cells lead to early endothelial damage, resulting in local thrombin
formation with subsequent irreversible platelet aggregation.
EXPERIMENTAL evidence has accumu-
lated indicating that the activation of
the blood clotting mechanism at the site
of tumour cell lodgement is a part of the
pathology of metastatic tumour growth
and in vivo observations in the rabbit
ear chamber demonstrated clot formation
around embolic tumour cells (Wood,
Holyoke and Yardley, 1961). Inhibitors
of blood coagulation or fibrinolytic agents
were shown to reduce blood bone meta-
stases in experimental conditions (Wood
et al., 1961; Cliffton and Agostino, 1965;
Agostino and Cliffton, 1965; Ryan, Ket-
cham and Wexler, 1968). It has been
concluded that fibrin formation around
adherent tumour cells is an important
step in the establishment of haemato-
genous metastases.
It was assumed that blood platelets
are involved in tumour cell lodgement
as well as participating in thrombus
formation, and that they may represent
an additional mediator of metastasis
formation (Gasic, Gasic and Stewart,
1968). The present investigations were
designed to obtain further information
about the behaviour of blood platelets
after administration of experimental tu-
mour cells into the blood stream. The
Walker carcinosarcoma 256 of the rat
was chosen for these experiments because
the ultrastructure of its intravascular
behaviour is fairly well investigated (Grif-
fith and Salsbury, 1963; Jones, Wallace
and Fraser, 1971; Warren and Vales,
1972). The use of the ascitic form
provides a suspension of single, viable
tumour cells which is easily obtained.
After the intravenous injection the major-
ity of the cells are arrested in the lungs,
representing the primary site ofmetastatic
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tumour growth (Cliffton et al., 1971).
Since the Walker carcinosarcoma 256 is
an allogeneic tumour, immunological reac-
tions which may complicate the experi-
mental results have to be taken into
account. However, only the initial phase
of tumour cell lodgement was studied in
the present experiments and for that
purpose the Walker carcinosarcoma 256
was considered to be an acceptable
tumour system.
MATERIALS AND METHODS
Female Wistar derived rats (inbred since
1953 at the Royal Postgraduate Medical
School, London), aged 5-6 weeks and weigh-
ing 110-150 g, were used throughout the
experiments.
The Walker carcinosarcoma 256, origin-
ated from a spontaneously grown mammary
adenocarcinoma (Stewart et al., 1959), was
transferred to the ascitic form (Agostino
and Clifton, 1968) using sterile techniques.
Subsequently the tumour was kept in the
ascitic form by intraperitoneal inoculation
of 2 x 106 freshly obtained tumour cells
into female rats (110-150 g). The intra-
muscular transplantation of 5 x 106 tumour
cells resulted in the animals' death 9-10 days
later, at which time the solid tumour had a
diameter of 3-4 cm. Six days after the
intraperitoneal inoculation the ascites was
harvested for the experiments. After wash-
ing and differential centrifugation at 4°C
with buffered saline (pH 7 4) containing 5%0
dextrose, the tumour cell suspension was
adjusted to the desired cell count with
buffered saline-500 dextrose.
The viability of the tumour cell suspen-
sions, or the suspensions of cell fragments,
was assessed by intramuscular transplanta-
tion of 5 x 106 cells into healthy control
animals.
Tumour cell fragments were prepared by
triple freezing and thawing of a tumour cell
suspension with a known cell count.
Finally, the fragments were washed and
resuspended in buffered saline to the original
volume. The supernatant was kept and
frozen for later platelet aggregation studies.
All injections were made during methoxy-
flurane (Penthrane, Abbott Laboratories
Ltd.) anaesthesia into the lateral tail veins
of the animals. In some instances tumour
cell suspensions were injected into the
thoracic aorta via a polyethylene cainula
inserted into the femoral artery.
Blood samples were obtained under
methoxyflurane anaesthesia by aortic punc-
ture and the blood was allowed to flow
directly into a polyethylene test tube con-
taining 2 mg of EDTA. Serial platelet
counts were performed from tail vein
blood.
Platelet counts were made in duplicate
(Brecher and Cronkite, 1950) and the plasma
fibrinogen was estimated according to the
method of Ratnoff and Menzie (1951).
The screening for fibrin monomers in plasma
was performed with the protamine precipita-
tion test (Sanfelippo, Stevens and Koenig,
1971).
Platelet aggregation was measured in a
platelet aggregation meter (Evans Electro-
selenium Ltd.) using rat platelet rich plasma
and 3808% sodium citrate (1: 10) as anti-
coagulant. Aggregating substances were sus-
pensions offreshlyprepared collagenparticles,
fresh tumour cell suspensions, tumour cell
fragments and tumour cell extracts. After
addition of the test sample the decrease of
light transmission was recorded.
Rat platelets from healthy donor animals
were labelled with 51Cr as described by
Dacie and Lewis (1968). 0 5 ml of platelet
rich plasma, containing approximately 9 x 105
labelled platelets per mm3 (corresponding to
approximately 8 x 104 ct/min) was injected
intraveouslyinto 24rats. Twenty-four hours
later a tumour cell suspension (5 x 106 cells)
was injected into 12 animals; 12 control
animals received the same volume of buf-
fered saline. Five minutes after the tumour
cell or saline injections the animals were
killed by rapid intraveous injection of
0-5 ml of Nembutal (Abbott Laboratories
Ltd.). Blood was obtained by heart punc-
ture before death. The right lung, parts
of the liver, the spleen and one kidney
were removed. After determination of the
wet weight the radioactivity was measured
in a conventional scintillation counter and
converted to ct/min/g tissue.
Twenty-four hours before the injection
of 5 x 106 tumour cells, 40 animals were
injected with labelled platelets as described.
The animals were divided into 5 groups and
pretreated with intravenous injections of
either heparin (Weddel Pharmaceuticals
Ltd.), dipyridamole (Persantin, Boehringer
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TABLE L.-Schedule of Treatment before the Intravenous Injection of 5x106 Tumour
Cells
Dose
750 u/kg b.w.
30 mg/kg b.w.
90 u/kg b.w.
0 5 ml
0-5 ml
Time before
tumour injection
(min)
15
15
10
15
30
Inge]heim), ancrod (Arvin, Twyford Labora-
tories) or 0-9% saline as outlined in Table I.
Five minutes after the tumour cell injection
the animals were killed, and blood and lung
radioactivity was determined according to
the procedure mentioned above. Immedi-
ately before death a blood sample from the
tail vein was obtained for platelet counts.
Five healthy control animals were injected
with 750 u/kg body weight of heparin and
platelet counts and whole blood clotting
times were performed before and 15 min
after the injection. Five additional control
animals were injected with 90 u/kg body
weight of ancrod and platelet counts were
determined before and 30 min after the
injection; the plasma fibrinogen level was
estimated 30 min after the injection.
The significance of the results obtained
in each experiment was established by the
Student t-test and the probability (P) was
estimated.
RESULTS
The intramuscular transplantation of
all tumour cell suspensions used in these
experiments initiated solid tumour growth
in healthy rats within 9-10 days, thus
corresponding to the growth pattern of
freshly obtained tumour cells. Triple
frozen and thawed tumour cells failed to
induce tumour growth when injected
intramuscularly.
Fig. 1 demonstrates the mean number
of blood platelets during the first 60
minutes following the intravenous injec-
tion of 7-5 x 106 freshly prepared Walker
carcinosarcoma 256 cells (n 10) and
cell fragments from the same amount of
tumour cells (n 6). The normal plate-
let count and its standard deviation were
established from 25 untreated female rats
(110-150 g). It is evident that there
platelets /mm3 [xlOO 000]
min
FIG. 1. Mean number of platelets followirng
the intravenous injection of 7 - 5 x 106
Walker carcinosarcoma 256 cells (Q O)
and tumour cell fragments (O O).
is no significant difference between the
effect of freshly prepared tumour cells
and tumour cell fragments upon the
number of circulating platelets. The
platelet count remains low during the
period of observation. Twenty-four hours
after the tumour cell injection the mean
platelet count was 420,000 (i120,000)
per mm3 and after 48 hours it had reached
normal values again.
The mean number of platelets 15
minutes after the intravenous and intra-
arterial injections of various amounts
of tumour cells is demonstrated in Table
II. Independent of the route of injection
there is a close correlation between the
number of tumour cells injected and
the decrease in circulating platelets.
However, the same amount of tumour
cells which produced a marked thrombo-
cytopenia ifinjected intravenously (5 x 106
cells) did not affect the platelet count if
Treatment
Heparin
Dipyridamole
Ancrod
Saline
Saline
No. of
animals
10
10
10
5
5
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TABLE II. Platelet Counts in Rats 15 Minutes after Intravenous (i.v.) or Intra-arterial
(i.a.) Injection of Various Amounts of Walker 256 Tumour Cells
Number of tumour Route of Standard No. of
cells injected injection Platelets/mm3 dleviation animals
2-5x 106
5 x 106
7 5x 106
1 5x 107
3x 107
6 x 107
Control
1.v.
i.v.
i.v.
i.a.
i.a.
i.a.
590000
384000
198000
685000
176000
16100
831000
± 105000
±52000
+ 46000
- 122000
4- 95000
± 6300
+114000
5
8
10
5
8
6
25
injected into the arterial side. A con-
siderable increase in the tumour cell
count is necessary to produce a com-
parable thrombocytopenia by intra-arte-
rial injection (Table II).
The organ distribution of 51Cr labelled
platelets 5 minutes after the intravenous
injection of 5 x 106 tumour cells is shown
in Fig. 2. The decrease of blood activity
and the increase of lung activity in the
tumour cell injected animals (n 12)
is highly significant (P in both cases
< 0.01) if compared with the control
group (n 12). The platelet distribu-
tion in the liver, spleen and kidneys is
identical in the 2 groups.
Table III demonstrates the mean
ct/min in the blood and the distribution
of 5'Cr labelled platelets in the lungs of
animals pretreated with various agents
5 minutes after the intravenous injection
cpm x103/g tissue
20
1 0
I -I-
3= control animals
m = tumour cell injected
I
of 5 x 106 tumour cells. The radio-
activity in the lungs and the blood
radioactivity had an inverse relationship.
Saline, dipyridamole and ancrod pre-
treatment did not influence the accumula-
tion of platelets in the lungs nor their
disappearance from the blood. These
groups are statistically not different from
each other. Heparin prevented the de-
crease of blood activity and the increase
in lung activity if compared with the other
treated groups (P < 0 01). The blood
activity in the various groups is closely
related to the amount of circulating
platelets, which is also demonstrated in
Table III.
The injection of 750 u/kg body weight
of heparin into otherwise untreated ani-
mals (n _ 5) prolonged the whole blood
clotting time from 2-5 (± 0.7) minutes
to over 30 minutes; the platelet count
was not altered by the heparin treatment.
Ninety u/kg body weight of ancrod
injected intravenously revealed the ab-
sence of clottable fibrinogen 30 minutes
after the injection (n 5); the platelet
count did not differ significantly from the
initial values.
The plasma fibrinogen level was deter-
mined in 12 control and 12 tumour cell
injected (5 x 106 cells) animals. The
tumour cell injected animals were bled
15 minutes (n 6) and 30 minutes
(n 6) after the injection. The mean
value for the control animals was 255
mg/100 ml (± 40 mg/l00 ml) against a
mean value in the tumour group of
230 mg/100 ml (± 45 mg/100 ml) at
15 minutes and 235 mg/100 ml (± 30
mg/100 ml) at 30 minutes. These dif-
blood lung liver spleen kidney
FIG. 2.--Distribution of 51Cr labelled platelets
in various organs 5 min after the intra-
venous injection of 5 x 106 Walker carcino-
sarcoma 256 cells or buffered saline.
rt , : 1 r , -j
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TABLE III. Platelet Counts and Distribution of 5'Cr-labelled Platelets in Blood and
Lungs 5 Minutes after the Intravenous Injection of 5x106 Tumour Cells into Rats
Pretreated with Variou,s Agents
ct/min x 102/g tissue -A~~~~~~~~~~
Lung
Mean s.d.
112 18
201 25
195 31
208 26
Blood
Mean s.d.
46 4-2
16 5-4
18 6-1
16 5 9
Platelets/mm3
Mean s.d.
701000 112000
335000 51000
370000 54000
362000 49000
ferences are statistically insignificant. In
all 12 plasma samples from the tumour
animals the protamine precipitation test
gave positive results, whereas in the
control plasmas only one out of 12 was
found positive.
The addition of a collagen suspension
to rat platelet rich plasma and the
recording of the changes in light trans-
mission in the aggregation meter resulted
in the well established curve for collagen
induced platelet aggregation. The addi-
tion of tumour cell suspensions up to a
concentration of 5 x 107 cells/ml did
not induce platelet aggregation. Tumour
cell fragments and extracts were equally
ineffective in producing platelet aggrega-
tion. The examination of tumour cell
platelet suspensions by phase contrast
microscopy did not suggest any inter-
action between these 2 types of cells.
DISCUSSION
Ultrastructural studies of embolic
Walker carcinosarcoma 256 cells reaching
the lung after intravenous injection re-
vealed that the cells were arrested singly
or in small groups in capillaries and
arterioles. The presence of a fibrin-like
meshwork around these cells was ob-
served. However, electron microscopy
studies failed to demonstrate significant
amounts of polymerized fibrin but num-
bers of platelets were surrounding the
tumour cells (Jones et al., 1971). Since
Gasic et al. (1968) reported that neur-
aminidase induced thrombocytopenia was
associated with a significant reduction
of experimental metastases in mice, some
consideration has been directed towards a
platelet-tumour cell interaction in the
lodgement ofhaematogenous tumour cells
(Gastpar, 1970; Kolenich, Mansour and
Flynn, 1972; Gasic, Gasic and Murphy,
1972; Wood and Hilgard, 1972). None
of the experimental data available allow
any conclusion concerning the mechanism
ofplatelet involvement in early metastasis
formation and it seemed desirable to
elucidate this phenomenon.
The immediate drop in the number
of circulating blood platelets following
the intravenous injection of a tumour
cell suspension obviously represents the
haematological counterpart to the mor-
phological finding of tumour cells asso-
ciated with platelet clusters (Jones et al.,
1971; Warren and Vales, 1972). The
correlation of the platelet decrease and
the number of tumour cells injected
seems to confirm this assumption. Iso-
tope studies demonstrated the rapid
disappearance of the platelets from the
circulation and their trapping in the
lungs-the primary site of tumour cell
lodgement. However, this phenomenon
is not dependent upon the presence of
living cells since the intravenous injection
of non-viable tumour cell fragments
initiated an identical decrease of cir-
culating platelets.
In contrast to Warren's (1970) finding
in the Chandler tube, neither fresh
Walker carcinosarcoma 256 cells nor
tumour cell fragments aggregated rat
Treatmeint,
Heparin
Dipyridamole
Ancrod
Saline
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platelets in vitro in the aggregation
meter. Furthermore, the injection of
Walker carcinosarcoma 256 cells into the
arterial side of the animals produced a
thrombocytopenia only when the number
oftumour cells was considerably increased.
These two facts suggest that the tumour
cell-platelet interaction is mediated in
vivo by additional mechanisms which for
their part are dependent upon local
factors.
Pretreatment with dipyridamole in
a dose which inhibits platelet aggregation
(Cucuianu, Nichizawa and Mustard, 1971)
was ineffective in preventing the tumour
cell induced decrease of blood platelets.
On the other hand, heparin completely
inhibited the development ofthe thrombo-
cytopenia. The lack of an increased
platelet accumulation in the lungs of
heparinized animals suggests that the
formation of tumour cell associated plate-
let aggregates was inhibited by heparin,
whereas dipyridamole was ineffective.
The presence of fibrin monomers
indicated that, in spite of the unchanged
plasma fibrinogen levels, intravascular
fibrin formation accompanied the con-
sumption of blood platelets. To study
the behaviour of blood platelets in the
absence of clottable fibrinogen, the ani-
mals were rendered afibrinogenaemic by
the injection of ancrod (a fraction of the
venom from the Malayan pit viper
Akistrodon rhodostoma). Ancrod induces
a state of hypofibrinogenaemia in various
laboratory animals by formation of intra-
vascular microclots which are rapidly
removed from the circulation (Ashford,
Ross and Southgate, 1968). The number
and function of circulating platelets are
not affected by this treatment (Davey
and Luischer, 1965). The identical pat-
tern of the platelet decrease and their
increased accumulation in the lung after
tumour cell injection in afibrinogenaemic
animals indicate that the formation of
thrombin at the site of tumour cell
lodgement is the crucial event. Throm-
bin induces intravascular platelet aggre-
gation and the platelet release reaction
earlier and at lower concentrations than
it induces fibrin formation (Mustard and
Packham, 1970). Ancrod prevents clot
formation by removing the clottable
protein; nevertheless, it does not interfere
with the generation of thrombin. On
the other hand, even low concentrations
of thrombin initiate the formation of
soluble intermediate polymers of the
fibrinogen-fibrin conversion and this poly-
merizing fibrin becomes associated with
platelets and causes their aggregation.
Inhibitors of the platelet release reaction
and of platelet aggregation, such as
dipyridamole, do not prevent this inter-
action (Niewiarowsky et al., 1972). Hepa-
rin of course, interferes with the formation
of thrombin and therefore probably in-
hibited the development of the thrombo-
cytopenia in this experimental model.
The degree of the thrombocytopenia
in the present experiments was highly
dependent upon the route of injection
of the tumour cells, which indicates that
local factors rather than tumour cell
related factors are involved in the genera-
tion of thrombin. Ashford and Frieman
(1968) demonstrated that minimal endo-
thelial trauma results in platelet clusters
associated with the surface of the endo-
thelium. If the endogenous fibrinolytic
response was inhibited by epsilon-amino
caproic acid pretreatment these platelets
were intimately associated with fibrin.
In view of previous light microscopy
studies (Wood, 1958) it seems justifiable
to assume that tumour cells induce such
minimal endothelial lesions at the site
of their arrest in the blood vessel. Breaks
in the plasma membrane, with exposure
of cytoplasmic contents of the endothelial
cells to the plasma, may lead to local
activation of the clotting mechanism with
formation of thrombin. Johnson et al.
(1965) concluded from their ultrastructural
studies that thrombin must form very
early after endothelial damage and that
it diffuses rapidly around the blood cells
in that area. The fact that non-viable
tumour cells and tumour cell membranes
behave identically with viable tumour
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cells in regard to their effect upon cir-
culating platelets further suggests that
the interaction of the tumour cell mem-
brane with the vascular endothelium and
its subsequent damage is the primary
event.
This work was supported by a grant
from the " Deutsche Forschungsgemein-
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